Healthcare | August 13, 2021
HCG Q1 revenue at Rs 326.58 cr. 67 per cent increase YoY
Substantial reduction in losses
Substantial reduction in losses
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
This work has been published in the journal ‘ACS applied materials and interface’
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
Under the PMBJP, all the districts of the country are covered and ensure easy reach of affordable medicine to the people in every nook and corner of the country
With the acquisition of these further shares, TWPL has now become company's subsidiary.
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
The company plans to enter the EU markets in FY22
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Subscribe To Our Newsletter & Stay Updated
